1 Jan 2013Article
Role of parathyroidectomy on anemia control and erythropoiesis-stimulating agent need in secondary hyperparathyroidism of chronic kidney disease. A retrospective study in 30 hemodialysis patients
Giovanni Conzo 1Alessandra Perna 2Cristina Pietra 1Daniela Esposito 1Anna Nunziata 1Antonietta Palazzo 1Alessandra Pizza 1Ersilia Satta 2Valerio Sciascia 1Luigi Santini 1
Affiliations
Article Info
1 Department of Anaesthesiologic, Surgical and Emergency Science, Seventh Division of General
2 Department of Cardio-thoracic and Respiratory Sciences, First Division of Nephrology
Ann. Ital. Chir., 2013, 84(1), 25-31;
Published: 1 Jan 2013
Copyright © 2013 Annali Italiani di Chirurgia
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
BACKGROUND: Parathyroidectomy (Ptx) ameliorates anemia (A) and reduces postoperative erythropoiesis-stimulating agent (ESA) requirement. The authors retrospectively evaluated the effects of successful Ptx on chronic A and ESA need in 30 2HPT patients. METHODS: From 2004 to 2009,30 anemic hemodialysis (HD) patients, affected by severe 2HPT, underwent Ptx -15 total parathyroidectomy (TP) and 15 TP + subcutaneous autoimplantation (TPai). Patients were evaluated for iPTH, hemoglobin (Hb) levels, erythrocyte count, hematocrit and erythropoietin dosing before and at 6, and 12 months after surgery. RESULTS: In every case, Ptx achieved a dramatic reduction of iPTH levels. In 26/30 cases(86.6%) an improvement of Hb levels was observed,and 27/30 (90%) patients did not need postoperative ESA treatment,irrespective of the type of surgical procedure carried out (TP or TPai). CONCLUSIONS: Successful Ptx for 2HPT of CKD determined a considerable improvement of A,reducing exogenous ESA need.In 2HPT of HD patients A is a secondary indication to surgical treatment,but we propose that this condition should be taken into more careful account, given the high costs of ESA therapy.
Keywords
- Anemia
- Chronic kidney disease
- Erythropoietin
- Parathyroidectomy
- Secondary hyperparathyroidism